Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor

被引:0
作者
Ciardiello, F
Caputo, R
Bianco, R
Damiano, V
Fentanini, G
Cuccato, S
De Placido, S
Bianco, AR
Tortora, G
机构
[1] Univ Naples Federico II, Fac Med & Chirurg, Dipartimento & Oncol Mol & Clin, Cattedra Oncol Med, I-80131 Naples, Italy
[2] Univ Pisa, Dipartimento Oncol, Div Anat Patol, I-56100 Pisa, Italy
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The transforming growth factor-alpha /epidermal growth factor receptor (TGF-ol-EGFR) autocrine pathway, which is involved in the development and the progression of human epithelial cancers, controls, in part, the production of angiogenic factors, These angiogenic factors, including vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), are secreted by cancer cells to stimulate normal endothelial cell growth through paracrine mechanisms. ZD1839 (Iressa) is a p,o,-active, selective EGFR-tyrosine kinase inhibitor (TKI) in clinical trials in cancer patients. In this study, we evaluated the antiangiogenic and antitumor activity of ZD1839 in human colon (GEO, SW480, and CaCo2), breast (ZR-75-1 and MCF-7 ADR), ovarian (OVCAR-3), and gastric (KATO III and N87) cancer cells that coexpress TGF-alpha and EGFR, ZD1839 treatment determined a dose- and time-dependent growth inhibition accompanied by the decrease of VEGF, bFGF and TGF-alpha production in vitro. Treatment of immunodeficient mice bearing well-established, palpable GEO xenografts with ZD1839 determined a cytostatic dose-dependent tumor growth inhibition. Immunohistochemical analysis of GEO tumor xenografts after ZD1839 treatment revealed a significant dose-dependent reduction of TGF-a, bFGF, and VEGF expression in cancer cells and of neoangiogenesis, as determined by microvessel count. Furthermore, the antitumor activity of ZD1839 was potentiated in combination with the cytotoxic drug paclitaxel in GEO tumor xenografts, Tumor regression was observed in all mice after treatment with ZD1839 plus paclitaxel, and it was accompanied by a significant potentiation in inhibition of TGF-a, VEGF, and bFGF expression with a few or no microvessels, Furthermore, 6 of 16 mice bearing well-established, palpable GEO xenografts had no histological evidence of GEO tumors at the end of treatment with ZD1839 plus paclitaxel, These results demonstrate that the antitumor effect of ZD1839 is accompanied by inhibition in the production of autocrine and paracrine growth factors that sustain autonomous local growth and facilitate angiogenesis, and that this effect can be potentiated by the combined treatment with certain cytotoxic drugs, such as paclitaxel.
引用
收藏
页码:1459 / 1465
页数:7
相关论文
共 29 条
[1]  
[Anonymous], 1995, The molecular basis of cancer
[2]   Type I Receptor Tyrosine Kinases as Targets for Therapy in Breast Cancer [J].
Baselga, Jose ;
Mendelsohn, John .
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 1997, 2 (02) :165-174
[3]  
Belotti D, 1996, CLIN CANCER RES, V2, P1843
[4]  
Bruns CJ, 2000, CANCER RES, V60, P2926
[5]  
Bruns CJ, 2000, CLIN CANCER RES, V6, P1936
[6]  
Ciardiello F, 2000, CLIN CANCER RES, V6, P3739
[7]  
Ciardiello F, 2000, CLIN CANCER RES, V6, P2053
[8]   Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A [J].
Ciardiello, F ;
Damiano, V ;
Bianco, R ;
Bianco, C ;
Fontanini, G ;
DeLaurentiis, M ;
DePlacido, S ;
Mendelsohn, J ;
Bianco, AR ;
Tortora, G .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (23) :1770-1776
[9]  
Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011
[10]   THE ROLE OF VASCULAR ENDOTHELIAL GROWTH-FACTOR IN PATHOLOGICAL ANGIOGENESIS [J].
FERRARA, N .
BREAST CANCER RESEARCH AND TREATMENT, 1995, 36 (02) :127-137